Entelromesis 75mg, 75mg FC tablets
PDF Leaflet Revision Date: 30 September 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Reduction of atherothrombotic events in adults with acute coronary syndrome.
Dosage (summary)
One tablet daily after initial loading dose.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Warfarin
- NSAIDs
- SSRIs
- CYP2C19 inhibitors
Contraindications
- Hypersensitivity to components
- Active bleeding
- Severe hepatic impairment
- Severe renal impairment
Common side effects
- Bleeding
- Dyspepsia
- Gastrointestinal hemorrhage
- Thrombocytopenia
Counselling Points
- Report unusual bleeding
- Avoid alcohol
- Inform healthcare providers before surgery
Serious warnings
- Risk of TTP
- Increased bleeding risk
- Gastrointestinal ulceration
Important Disclaimer
The Entelromesis 75mg, 75mg FC tablets professional information leaflet below is the property of Pharma Dynamics and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
